Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRALS
2024-512536-29-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing VHB937 arm with Placebo arm (2 arms). Primary endpoint: Composite of PAV-free survival and change in ALSFRS-R (CAFS). Planned start Jan 2025; status: authorised.
02
Drugs
VHB937
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-512536-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512536-29-00.